Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 10.57
DXCM's Cash to Debt is ranked higher than
80% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. DXCM: 10.57 )
DXCM' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 10.57

Equity to Asset 0.71
DXCM's Equity to Asset is ranked higher than
80% of the 303 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. DXCM: 0.71 )
DXCM' s 10-Year Equity to Asset Range
Min: -0.63   Max: 0.92
Current: 0.71

-0.63
0.92
F-Score: 6
Z-Score: 43.63
M-Score: -3.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -13.07
DXCM's Operating margin (%) is ranked higher than
59% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.78 vs. DXCM: -13.07 )
DXCM' s 10-Year Operating margin (%) Range
Min: -2272.81   Max: -18.06
Current: -13.07

-2272.81
-18.06
Net-margin (%) -13.52
DXCM's Net-margin (%) is ranked higher than
59% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.12 vs. DXCM: -13.52 )
DXCM' s 10-Year Net-margin (%) Range
Min: -2147.42   Max: -18.63
Current: -13.52

-2147.42
-18.63
ROE (%) -27.21
DXCM's ROE (%) is ranked higher than
57% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.58 vs. DXCM: -27.21 )
DXCM' s 10-Year ROE (%) Range
Min: -644.81   Max: -35.43
Current: -27.21

-644.81
-35.43
ROA (%) -19.40
DXCM's ROA (%) is ranked higher than
56% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.35 vs. DXCM: -19.40 )
DXCM' s 10-Year ROA (%) Range
Min: -134.12   Max: -24.33
Current: -19.4

-134.12
-24.33
ROC (Joel Greenblatt) (%) -71.00
DXCM's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.02 vs. DXCM: -71.00 )
DXCM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1666.94   Max: -98.63
Current: -71

-1666.94
-98.63
Revenue Growth (%) 38.30
DXCM's Revenue Growth (%) is ranked higher than
98% of the 280 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.20 vs. DXCM: 38.30 )
DXCM' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 103.1
Current: 38.3

0
103.1
EBITDA Growth (%) -25.50
DXCM's EBITDA Growth (%) is ranked higher than
52% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. DXCM: -25.50 )
DXCM' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 0.6
Current: -25.5

0
0.6
EPS Growth (%) -24.30
DXCM's EPS Growth (%) is ranked higher than
55% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. DXCM: -24.30 )
DXCM' s 10-Year EPS Growth (%) Range
Min: -40.1   Max: 37.1
Current: -24.3

-40.1
37.1
» DXCM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

DXCM Guru Trades in Q3 2013

Jim Simons 207,343 sh (+77%)
Mario Gabelli 75,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
George Soros Sold Out
Ron Baron 1,369,154 sh (-1.29%)
RS Investment Management 621,381 sh (-16.03%)
» More
Q4 2013

DXCM Guru Trades in Q4 2013

Paul Tudor Jones 8,059 sh (New)
Jim Simons 557,543 sh (+168.9%)
Ron Baron 1,357,357 sh (-0.86%)
Mario Gabelli 74,000 sh (-1.33%)
RS Investment Management 477,381 sh (-23.17%)
» More
Q1 2014

DXCM Guru Trades in Q1 2014

Steven Cohen 13,332 sh (New)
RS Investment Management 496,081 sh (+3.92%)
Ron Baron 1,354,112 sh (-0.24%)
Mario Gabelli 71,000 sh (-4.05%)
Paul Tudor Jones 7,198 sh (-10.68%)
Jim Simons 380,843 sh (-31.69%)
» More
Q2 2014

DXCM Guru Trades in Q2 2014

Joel Greenblatt 8,033 sh (New)
RS Investment Management 538,660 sh (+8.58%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Ron Baron 1,348,572 sh (-0.41%)
Mario Gabelli 70,500 sh (-0.7%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy$29.68 - $41.95 $ 41.517%8033
George Soros 2013-09-30 Sold Out 0.02%$21.78 - $29.19 $ 41.564%0
George Soros 2013-03-31 New Buy0.02%$13.59 - $17.05 $ 41.5173%100000
Ron Baron 2012-12-31 New Buy0.11%$12.3 - $14.95 $ 41.5210%1250000
George Soros 2011-09-30 Sold Out 0.0025%$10.3 - $15.66 $ 41.5220%0
George Soros 2011-06-30 New Buy$13.05 - $16.72 $ 41.5172%12500
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about DexCom Inc

Top Insider Sells Highlight: Dexcom Inc.
CEO, 10% Owner of Dexcom Inc (DXCM) Terrance H Gregg sold 23,893 shares on 08/21/2014 at an average price of $44.36. The total transaction amount was $1,059,893. Read more...

Ratios

vs
industry
vs
history
P/B 31.50
DXCM's P/B is ranked higher than
52% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. DXCM: 31.50 )
DXCM' s 10-Year P/B Range
Min: 3.88   Max: 209.25
Current: 31.5

3.88
209.25
P/S 15.20
DXCM's P/S is ranked higher than
52% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. DXCM: 15.20 )
DXCM' s 10-Year P/S Range
Min: 6.36   Max: 1058.5
Current: 15.2

6.36
1058.5
EV-to-EBIT -116.64
DXCM's EV-to-EBIT is ranked lower than
52% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.10 vs. DXCM: -116.64 )
DXCM' s 10-Year EV-to-EBIT Range
Min: 1   Max: 4.1
Current: -116.64

1
4.1
Current Ratio 2.96
DXCM's Current Ratio is ranked higher than
76% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.92 vs. DXCM: 2.96 )
DXCM' s 10-Year Current Ratio Range
Min: 1.96   Max: 23.47
Current: 2.96

1.96
23.47
Quick Ratio 2.64
DXCM's Quick Ratio is ranked higher than
81% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. DXCM: 2.64 )
DXCM' s 10-Year Quick Ratio Range
Min: 1.82   Max: 23.47
Current: 2.64

1.82
23.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 148.22
DXCM's Price/Net Cash is ranked higher than
86% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. DXCM: 148.22 )
DXCM' s 10-Year Price/Net Cash Range
Min: 4.94   Max: 166
Current: 148.22

4.94
166
Price/Net Current Asset Value 64.84
DXCM's Price/Net Current Asset Value is ranked higher than
81% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. DXCM: 64.84 )
DXCM' s 10-Year Price/Net Current Asset Value Range
Min: 4.94   Max: 207
Current: 64.84

4.94
207
Price/Tangible Book 33.74
DXCM's Price/Tangible Book is ranked higher than
59% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.22 vs. DXCM: 33.74 )
DXCM' s 10-Year Price/Tangible Book Range
Min: 4.7   Max: 154.75
Current: 33.74

4.7
154.75
Price/Median PS Value 1.05
DXCM's Price/Median PS Value is ranked higher than
76% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. DXCM: 1.05 )
DXCM' s 10-Year Price/Median PS Value Range
Min: 0.55   Max: 46.83
Current: 1.05

0.55
46.83
Forward Rate of Return (Yacktman) -22.11
DXCM's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 258 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. DXCM: -22.11 )
DXCM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 36.5   Max: 57
Current: -22.11

36.5
57

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:DC4.Germany
Dexcom Inc is a Delaware Corporation, incepted in May 1999. It is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The majority of its product revenue comes from sales of its SEVEN PLUS ambulatory continuous glucose monitoring system. The Company's SEVEN PLUS is more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. The SEVEN PLUS incorporates additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate and customizable. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. The new SEVEN PLUS is an easy-to-use wireless device that is designed to simplify the patient's glucose management. The SEVEN PLUS measures the patient's glucose 24/7. It shows a new glucose reading every 5 minutes and updates the trend-wave to show the where glucose level is, where it has been, and where it's headed. The SEVEN PLUS also shows how fast the body's glucose levels are changing. The SEVEN PLUS is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Glucose data can be displayed on the monitor at one hour, 3 hours, 6 hours, 12 hours and 24 hours.
» More Articles for DXCM

Headlines

Articles On GuruFocus.com
Top Insider Sells Highlight: Dexcom Inc. Aug 22 2014 
DexCom Reports $1 Million Insider Buy Mar 12 2013 
DexCom Inc. Reports Operating Results (10-Q) Aug 03 2010 
DexCom Inc. Reports Operating Results (10-Q) May 05 2010 
DexCom Inc. Reports Operating Results (10-Q) Nov 04 2009 
DexCom Inc. Reports Operating Results (10-Q) Aug 03 2009 
DexCom Inc. Reports Second Quarter 2009 Financial Results Aug 03 2009 
DexCom Inc. (DXCM) CEO Terrance H Gregg buys 20,000 Shares May 14 2009 
DexCom Inc. Reports Operating Results (10-Q) May 06 2009 
DexCom Inc. (DXCM) CEO Terrance H Gregg buys 50,000 Shares Mar 17 2009 

More From Other Websites
3 Stocks Dragging The Health Services Industry Downward Sep 03 2014
[video] A sensor to swallow with your medicine Aug 25 2014
Top Insider Sells Highlight: Dexcom Inc. Aug 22 2014
DexCom Continues to Gain; Enters Data Integration Deal Aug 14 2014
DEXCOM INC Financials Aug 13 2014
DexCom Sees Narrower Q2 Loss; Revenues Top Estimates Aug 07 2014
Trade-Ideas: DexCom (DXCM) Is Today's "Barbarian At The Gate" Stock Aug 07 2014
Dexcom Announces Data Integration Relationship with Asante Solutions, Makers of the Snap™ Insulin... Aug 07 2014
DEXCOM INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2014
DexCom, Inc. Reports Second Quarter 2014 Financial Results Aug 06 2014
Q2 2014 DEXCOM INC Earnings Release - After Market Close Aug 06 2014
Insulet and Dexcom Agree to Develop a CGM-Integrated Personal Diabetes Manager Aug 05 2014
Jay D. Miller, the President and CEO of IMRIS Inc. (IMRS), Interviews with The Wall Street... Aug 01 2014
DexCom to Present at Canaccord Genuity 34th Annual Growth Conference Jul 31 2014
DexCom Schedules Second Quarter 2014 Earnings Release and Conference Call for August 6, 2014 at 4:30... Jul 23 2014
5 New Medical Technologies For Diabetics Jul 18 2014
DEXCOM INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 07 2014
DexCom Collaborates with Insulet Corporation Jun 16 2014
Freedom for Diabetics as Bionic Pancreas Passes Testing Jun 15 2014
Diabetics Get Freedom in Bionic Pancreas Real-World Trial Jun 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK